Kathrin Abbrederis-Philipp

Innsbruck, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Austrian Real-world Experience With Standard of Care Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle-Cell Lymphoma.

Austrian Real-world Experience With Standard of Care Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: August 26, 2025

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies.

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies.

Journal: HemaSphere

Published: November 23, 2021

Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.

Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 17, 2020

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.

Journal: Therapeutic advances in medical oncology

Published: July 04, 2019

What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016.

What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016.

Journal: Future oncology (London, England)

Published: July 08, 2017

Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.

Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.

Journal: Haematologica

Published: January 18, 2016

First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.

First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 22, 2015

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.

Journal: EMBO molecular medicine

Published: March 05, 2015

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.

Journal: Theranostics

Published: December 06, 2014

Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma.

Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma.

Journal: American journal of nuclear medicine and molecular imaging

Published: September 22, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026